Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
MRX34 is a liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity through inhibition of MYC, MET, BCL2, CCND1 and CTNNB1 (NCI Drug Dictionary; PMID: 24657911).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MRX34||BCL2 inhibitor 17 c-MYC Inhibitor 9 MET Inhibitor 51||MRX34 is a liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity through inhibition of MYC, MET, BCL2, CCND1 and CTNNB1 (PMID: 24657911, PMID: 32238921).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||MRX34||Phase I||Actionable||In a Phase I trial, MRX34 treatment in advanced solid tumor patients resulted in some preliminary efficacy, including a partial response lasting 48 weeks in one patient with hepatocellular carcinoma and four patients with stable disease (PMID: 27917453).||27917453 detail...|
|Unknown unknown||malignant glioma||not applicable||MRX34||Preclinical||Actionable||In a preclinical study, MRX34 (miR-34a) induced apoptosis and inhibited growth of glioma cells in culture and in xenograft models (PMID: 19773441).||19773441|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01829971||Phase I||MRX34||A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection||Terminated|